NASDAQ:INOInovio Pharmaceuticals Stock Price, Forecast & News

Inovio Pharmaceuticals' stock was trading at $8.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INO stock has increased by 48.5% and is now trading at $12.43. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Inovio Pharmaceuticals.

Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Inovio Pharmaceuticals.

Inovio Pharmaceuticals Inc (NASDAQ:INO) issued its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.04. The biopharmaceutical company had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.55 million. Inovio Pharmaceuticals had a negative net margin of 4,700.42% and a negative return on equity of 166.85%. During the same quarter in the previous year, the firm earned ($0.30) EPS. View Inovio Pharmaceuticals' earnings history.

Inovio Pharmaceuticals's stock reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

10 analysts have issued 1 year price targets for Inovio Pharmaceuticals' shares. Their forecasts range from $4.00 to $19.00. On average, they expect Inovio Pharmaceuticals' share price to reach $12.33 in the next twelve months. This suggests that the stock has a possible downside of 0.8%. View analysts' price targets for Inovio Pharmaceuticals.

Media coverage about INO stock has trended somewhat positive on Wednesday, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Inovio Pharmaceuticals earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutInovio Pharmaceuticals.

Some companies that are related to Inovio Pharmaceuticals include Hill-Rom (HRC), Novocure (NVCR), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), Nevro (NVRO), ICU Medical (ICUI), Irhythm Technologies (IRTC), NuVasive (NUVA), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP), AtriCure (ATRC) and Cantel Medical (CMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Gilead Sciences (GILD), Advanced Micro Devices (AMD), NVIDIA (NVDA), Micron Technology (MU), Novavax (NVAX), Anavex Life Sciences (AVXL), Moderna (MRNA), Johnson & Johnson (JNJ), Opko Health (OPK) and Alibaba Group (BABA).

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Inovio Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.91%), Wasatch Advisors Inc. (2.47%), VR Adviser LLC (1.83%), Nikko Asset Management Americas Inc. (1.86%), Sumitomo Mitsui Trust Holdings Inc. (1.86%) and Nikko Asset Management Americas Inc. (1.86%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Laurent Humeau and Peter Kies. View institutional ownership trends for Inovio Pharmaceuticals.

INO stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Morgan Stanley, Defender Capital LLC., UBS Group AG, and TIAA FSB. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, and Jong Joseph Kim. View insider buying and selling activity for Inovio Pharmaceuticals.

INO stock was bought by a variety of institutional investors in the last quarter, including VR Adviser LLC, BlackRock Inc., Balyasny Asset Management LLC, Geode Capital Management LLC, Nuveen Asset Management LLC, State Street Corp, IFG Advisory LLC, and Invesco Ltd.. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Jong Joseph Kim, and Laurent Humeau. View insider buying and selling activity for Inovio Pharmaceuticals.

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INO stock can currently be purchased for approximately $12.43.

Inovio Pharmaceuticals has a market capitalization of $1.97 billion and generates $4.11 million in revenue each year. The biopharmaceutical company earns $-119,360,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Inovio Pharmaceuticals employs 281 workers across the globe.

The official website for Inovio Pharmaceuticals is www.inovio.com.

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]